Search

Your search keyword '"Enrico Caserta"' showing total 2 results
Start Over Author "Enrico Caserta" Journal blood advances
2 results on '"Enrico Caserta"'

1. Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting

Author

Domenico Viola, Hongzhi Li, Xiwei Wu, Flavia Pichiorri, James F. Sanchez, Timothy W. Synold, Steven T. Rosen, Ralf Buettner, Michael Rosenzweig, Austin Christofferson, Amrita Krishnan, Jonathan J Keats, Alex E. Pozhitkov, Nagarajan Vaidehi, Estelle Troadec, Joycelynne Palmer, Jihane Khalife, Enrico Caserta, Guido Marcucci, Corey Morales, and Emine Gulsen Gunes

Subjects
Drug synergism, Proto-Oncogene Proteins c-myc, Mice, chemistry.chemical_compound, Proto-Oncogene Proteins c-pim-1, In vivo, hemic and lymphatic diseases, Teriflunomide, Tumor Cells, Cultured, medicine, Animals, Humans, Enzyme Inhibitors, Lenalidomide, Active metabolite, Leflunomide, Drug Synergism, Hematology, Stimulus Report, chemistry, Pim kinases, Cancer research, Drug Therapy, Combination, Multiple Myeloma, Combination method, medicine.drug
Abstract

Key Points Teriflunomide, the active metabolite of leflunomide, downregulates c-Myc expression through inhibition of PIM kinases. Leflunomide together with lenalidomide significantly extended survival in an in vivo MM model.

Published
2019

2. Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab

Author

Van Eric Biglang-awa, Jeffrey Y.C. Wong, Nitya Nathwani, Flavia Pichiorri, Stephen J. Forman, Michael Rosenzweig, Arnab Chowdhury, Dave Yamauchi, Chatchada Karanes, Guido Marcucci, Russell Rockne, Paul J. Yazaki, Amrita Krishnan, Joycelynne M. Palmer, Anna M. Wu, Nicole Bowles, Enrico Caserta, David Colcher, Erasmus Poku, Vikram Adhikarla, Maria Parayno, Ammar Chaudhry, John E. Shively, Jennifer Simpson, James F. Sanchez, and Firoozeh Sahebi

Subjects
medicine.diagnostic_test, Immunobiology and Immunotherapy, business.industry, Daratumumab, Antibodies, Monoclonal, Hematology, CD38, medicine.disease, ADP-ribosyl Cyclase 1, chemistry.chemical_compound, Text mining, chemistry, Copper Radioisotopes, Positron emission tomography, In vivo, Positron Emission Tomography Computed Tomography, medicine, DOTA, Humans, Copper-64, Nuclear medicine, business, Multiple Myeloma, Multiple myeloma
Abstract

18F-Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is one of the most widely used imaging techniques to detect multiple myeloma (MM). Intracellular FDG uptake depicts in vivo metabolic activity, which can be seen in both malignant and nonmalignant cells, resulting in limited sensitivity and specificity. Our group showed preclinically that tracing MM dissemination using a CD38-directed human antibody, daratumumab, that is radioconjugated with 64Cu via the chelator DOTA (64Cu-daratumumab), led to improved sensitivity and specificity over that of FDG. Here, we report the results of a phase 1 trial designed to (1) assess the safety and feasibility of 64Cu-daratumumab PET/CT and (2) preliminarily evaluate and characterize the ability of 64Cu-daratumumab to accurately detect or exclude MM lesions. A total of 12 daratumumab-naive patients were imaged. Prior to the injection of 15 mCi/5 mg of 64Cu-daratumumab, patients were treated with 0 (n = 3), 10 (n = 3), 45 (n = 3), or 95 mg (n = 3) of unlabeled daratumumab to assess its effect on image quality. No significant adverse events were observed from either unlabeled daratumumab or 64Cu-daratumumab. Of the dose levels tested, 45 mg unlabeled daratumumab was the most optimal in terms of removing background signal without saturating target sites. 64Cu-daratumumab PET/CT provided safe whole-body imaging of MM. A trial comparing the sensitivity and specificity of 64Cu-daratumumab PET/CT with that of FDG PET/CT is planned. This trial was registered at www.clinicaltrials.gov as #NCT03311828.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results